Wedbush Has Bearish Forecast for ARTV FY2024 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at Wedbush cut their FY2024 earnings per share estimates for Artiva Biotherapeutics in a research note issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($5.08) for the year, down from their prior estimate of ($4.55). Wedbush has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.60) per share. Wedbush also issued estimates for Artiva Biotherapeutics’ FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.76) EPS and FY2027 earnings at ($2.91) EPS.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24).

Several other analysts also recently issued reports on ARTV. Jefferies Financial Group assumed coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating and a $21.00 price target for the company. TD Cowen began coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating on the stock. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday. Finally, Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Trading Down 10.2 %

Shares of ARTV opened at $10.51 on Friday. Artiva Biotherapeutics has a 12 month low of $9.68 and a 12 month high of $17.31. The business’s fifty day simple moving average is $12.60.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds have recently bought and sold shares of ARTV. BNP Paribas Financial Markets acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at about $42,000. MetLife Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $135,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Artiva Biotherapeutics in the third quarter valued at $623,000. Finally, Acuta Capital Partners LLC acquired a new stake in Artiva Biotherapeutics during the third quarter worth $680,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.